Company: CWAN
Filing Date: 2025-03-20
Form Type: 424B3
Source: 0001193125-25-058975
Chunk: 81

Company: Clearwater Analytics Holdings, Inc.
Filing Date: 2025-03-20
Form: 424B3
Chunk 81
---
 the Special Meeting.

If you sign and return a proxy and
do not indicate how you wish to vote on any proposal, or if you indicate that you wish to vote in favor of the Merger Agreement Proposal but do not indicate a choice on the Adjournment Proposal, your shares of Enfusion Common Stock or Enfusion
Class B Common Stock will be voted in favor of the Adjournment Proposal. If you indicate, however, that you wish to vote against the Merger Agreement Proposal, your shares of Enfusion Common Stock or Enfusion Class B Common Stock will only
be voted in favor of the Adjournment Proposal if you indicate that you wish to vote in favor of the Adjournment Proposal. If the Special Meeting is so adjourned, Enfusion Stockholders who have already submitted their proxies will be able to revoke
them at any time prior to their use.

The affirmative vote, virtually or by proxy, of a majority of the votes properly cast by holders of
shares of Enfusion Common Stock and Enfusion Class B Common Stock represented at the Special Meeting is required to approve the Adjournment Proposal.

THE ENFUSION BOARD UNANIMOUSLY RECOMMENDS THAT ENFUSION STOCKHOLDERS VOTE “FOR” THE ADJOURNMENT PROPOSAL.

51

THE TRANSACTIONS This section of the Proxy Statement/Prospectus describes the material aspects of the proposed Merger. This section may not contain all of the information that is important to you. You should carefully read this entire Proxy Statement/Prospectus and the documents incorporated by reference into this Proxy Statement/Prospectus, including the full text of the Merger Agreement, a copy of which is attached to this Proxy Statement/Prospectus as Annex A , for a more complete understanding of the proposed Merger and the transactions related thereto. Effects of the Transactions The Merger Agreement provides that, through a series of transactions including the Merger, the LLC Merger and, if certain conditions have been satisfied as of the Closing Date but prior to the Effective Time, the Second Merger, Enfusion or Acquirer (as successor in interest to Enfusion in the event the Second Merger occurs) will become a direct, wholly-owned subsidiary of Clearwater and Enfusion OpCo will become an indirect subsidiary of Clearwater. LLC Merger At Closing, Merger Sub II will merge with and into Enfusion OpCo. Enfusion OpCo will be the surviving entity of the LLC Merger (